Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Tamoxifen Therapy and Ovarian Function

Evaluating long-term use and effectiveness

Tamoxifen (TAM) use in the absence of chemotherapy was not associated with an earlier age onset of menopause in patients with ductal carcinoma in situ (DCIS) or invasive breast cancer and is unlikely to significantly accelerate ovarian aging, according to a study of 250 women, half of which received TAM and half who did not. Mean age of menopause onset was 51 for both groups and was not associated with duration of TAM use or the age at TAM initiation. Researchers found:

• Menstrual pattern changes were more frequent in the TAM group than control group.

• Older age was associated with an increased risk of developing amenorrhea within 6 months of starting TAM.

• Menstrual pattern changes are common in premenopausal women taking TAM.

Citation: Chien AJ, Duralde E, Hwang R, et al. Association of tamoxifen use and ovarian function in patients with invasive or pre-invasive breast cancer. Breast Cancer Res Treat. [Published online ahead of print, July 25, 2015]. doi:10.1007/s10549-015-3511-3.